Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 280

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 280
---
 officers, directors and advisors, and the Company’s current shareholders have in the Business Combination?” Regulatory Approvals Required for the Business Combination Non -U.S. regulatory bodies and U.S. state attorneys general could take action under other applicable regulatory laws as they deem necessary or desirable in the public interest, including, without limitation, seeking to enjoin or otherwise prevent the completion of the Business Combination or permitting completion subject to regulatory conditions. Private parties may also seek to take legal action under regulatory laws under some circumstances. There can be no assurance that a challenge to the Business Combination on antitrust grounds will not be made or, if such a challenge is made, that it would not be successful. APx and the Company are not aware of any other regulatory approvals in the United States and Cayman Islands or elsewhere required for the consummation of the Business Combination.

134 Litigation Relating to the Business Combination There have been no proceedings brought against APx in relation to the Business Combination or the Business Combination Agreement. Listing of Company Shares Approval of the listing on Nasdaq of the Company Shares to be issued in the Business Combination, subject to official notice of issuance, is a condition to each party’s obligation to complete the Business Combination. Accounting Treatment of the Business Combination OmnigenicsAI will account for the Business Combination as a capital reorganization in accordance with IFRS as issued by the IASB. Under this method of accounting, APx will be treated as the “acquired” company for financial reporting purposes and OmnigenicsAI will be the accounting “acquirer.” This determination was primarily based on the assumptions that OmnigenicsAI’s shareholders will hold a majority of the voting power of the Combined Company, OmnigenicsAI’s operations will substantially comprise the ongoing operations of the Combined Company, OmnigenicsAI’s designees are expected to comprise a majority of the governing body of the Combined Company, and OmnigenicsAI’s senior management will comprise the senior management of the Combined Company. APx does not meet the definition of a “business” pursuant to IFRS3, Business Combinations, and thus, for accounting purposes, OmnigenicsAI will account for the Business Combination as a capital reorganization. The net assets of APx will be stated at historical cost, with no goodwill or other intangible assets recorded. The Business Combination will be accounted for within the scope of IFRS 2. As a result, any excess of fair value of the Company Shares issued over the fair value of APx’s identifiable net assets acquired